Preclinical oncology

Cancer treatment.Powered byphysics.

We are developing a new class of targeted therapeutics that use light-triggered energy release to physically destroy tumors.

Conceptual illustration

N10 TherapeuticsPrecision targetingControlled activationEnergetic ablation

The platform

Precision targeting meets
energetic ablation.

N10 combines tumor-targeting molecules, carbon nanotubes and an energetic payload in a modular nanotherapeutic. Near-infrared light is intended to trigger localized heat release within the treatment area.

N10 platform concept Tumor-cell destruction may release tumor antigens and immune-stimulating signals that help prime an antitumor immune response. The illustration shows released antigens reaching an immune cell. This potential benefit remains under investigation. TARGETED NANOMATERIAL TUMOR CELL NEAR-INFRARED LIGHT LOCAL HEAT RELEASE IMMUNE PRIMING TUMOR ANTIGENS

Platform concept · Not to scale · Select a step to explore

A physical approach to a biological challenge.

Tumors can escape treatments that depend on a particular molecular pathway. N10 is developing an approach in which heat delivers the final tumor-killing effect.

Control over where treatment acts

Targeting and illumination are designed to work together to focus energy release within the intended treatment area.

Greater local heat generation

The energetic payload is designed to amplify heating, with the goal of reducing the laser energy required for tumor ablation.

Our lead program

Starting with
prostate cancer.

Our lead program explores PSMA-targeted energetic nanotherapy for localized prostate cancer. We are developing antibody targeting approaches alongside a laser-activated formulation for focal tumor ablation.

Lead indication
Localized prostate cancer
Targeting approach
PSMA-directed delivery
Development stage
Preclinical

A modular platform. Our longer-term aim is to adapt the targeting component for other solid tumors. Research priorities include thermal control, tumor selectivity and the potential for antitumor immune responses.

The scientific founders

Built by the scientists
behind the platform.

Bringing cancer biology, translational medicine and energetic materials together.

Mark Trifiro

Co-founder

Mark TrifiroMD

Medicine & clinical translation

Physician-scientist with expertise in endocrinology, prostate cancer and the translation of nanomedicine research.

Miltiadis Paliouras

Co-founder

Miltiadis PaliourasPhD

Cancer biology & nanomedicine

Cancer researcher with experience in prostate and breast cancer biology, targeted nanotherapies and molecular diagnostics.

Davin G. Piercey

Co-founder

Davin G. PierceyPhD

Energetic materials

Chemist specializing in nitrogen-rich energetic materials and the relationship between molecular structure and energy release.

Connect with N10

Help bring a new
approach to cancer.

We welcome conversations with research collaborators, development partners and investors.

Contact N10